Teeter AE, et al. – This study was designed to elucidate whether early prostate–specific antigen doubling time (ePSADT), computed from the first detectable post–operative prostate–specific antigen up to and including the first recurrence value, correlates with prostate cancer outcomes. Early prostate–specific antigen doubling time <9 months, calculated applying prostate–specific antigen values before and up to biochemical recurrence, is correlated with increased risk of castration–resistant prostate cancer, metastases, prostate–cancer specific mortality, and all–cause mortality among men with biochemical recurrence after RP. Moreover, ePSADT allows for risk–stratification at BCR and before PSADT is calculable allowing these men to be referred for early aggressive secondary treatment and/or clinical trials.